Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization
July 17 2024 - 6:05AM
Business Wire
MMS, a data-focused clinical research organization (CRO),
announced today that Ben Dudley has been appointed as the company’s
new Chief Commercial Officer (CCO). Based in the UK, Ben Dudley
brings more than 25 years of life sciences expertise on the CRO and
Sponsor side, holding previous operational and commercial
leadership roles at Parexel, Covance, and AstraZeneca.
As CCO at MMS, Ben will focus on:
- Strategic growth planning, working closely with other members
of the Executive Leadership Team (ELT) to refine the vision,
strategy, and goals for continued growth and expansion of MMS
globally.
- Commercial leadership, understanding sponsor needs and guiding
customer relationship management across global accounts; and
- Marketing strategy, overseeing campaigns that showcase the
value-add of MMS service offerings, which will impact our customer
successes as well as have a positive impact on patient health.
“We were deliberate in our choice of a CCO who brings scientific
strength, agility, and leadership to help continue to move MMS
forward, and Ben’s experience is a great fit,” said Dr. Uma Sharma,
CEO of MMS. “Ben’s passion for our industry, his commercial
expertise, and proven leadership give us added momentum to drive
our strategic vision, foster key partnerships, and significantly
enhance our market presence.”
Data excellence is the need of the hour and what MMS brings
to the industry.
"I am thrilled to join MMS at such an exciting time in the
company's evolution," said Ben Dudley. "The company holds a
significant place in the global CRO landscape, and I have witnessed
the strength of their expertise over the years. I relish the
opportunity to be part of the leadership of an organization with
unique capabilities and culture as we continue the next stage of
growth and delivery for our customers.”
This year, MMS celebrates 18 years globally, recently being
named a Great Place to Work in all major regions of the world. MMS
is known globally for data-focused CRO services, including:
- Bundled Biometrics solutions, starting with the IND,
effectively managing all data collection, analysis, and integrating
non-traditional data and submission analyses.
- Regulatory submissions, beginning with global regulatory
strategy for multiple markets followed by execution of successful
marketing applications (data, writing, and publishing/submission)
with a flawless track record and industry leadership with over 50
submissions completed in the past five years.
- Other key areas, including Regulatory and Medical
Writing from IND to Phase 3, Quality and Compliance (complete GxP
globally), Drug Safety and Pharmacovigilance, Clinical Trial
Transparency, and more.
View the entire MMS Executive Leadership Team (ELT) at
https://www.mmsholdings.com/executive-leadership/
About MMS
MMS Holdings (MMS) is an award-winning, data-focused clinical
research organization (CRO) that supports the pharmaceutical and
biotech industries with a proven, scientific approach to complex
trial data and regulatory submission challenges. Strong industry
experience, an 18-year track record, AI technology-enabled
services, and a data-driven approach to drug development make MMS a
valuable CRO partner. With a global footprint across four
continents, MMS maintains an industry-leading customer satisfaction
rating.
For more information, visit www.mmsholdings.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240717384423/en/
Media Prasad Babu media@mmsholdings.com